Cimifugin ameliorates Crohn's disease-like colitis in mice by modulating Th-cell immune balance via inhibiting the MAPK pathway.
10.12122/j.issn.1673-4254.2025.03.17
- Author:
Lixia YIN
1
;
Minzhu NIU
2
;
Keni ZHANG
1
;
Zhijun GENG
2
;
Jianguo HU
1
;
Jiangyan LI
1
;
Jing LI
1
Author Information
1. Department of Clinical Laboratory, Bengbu Medical University, Bengbu, 233000, China.
2. Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-Related Diseases, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233000, China, Bengbu Medical University, Bengbu, 233000, China.
- Publication Type:Journal Article
- Keywords:
Crohn's disease;
MAPK;
cimifugin;
helper T cells;
immune homeostasis;
intestinal barrier
- MeSH:
Animals;
Mice, Inbred C57BL;
Male;
Mice;
Crohn Disease/immunology*;
Colitis/immunology*;
MAP Kinase Signaling System/drug effects*;
Trinitrobenzenesulfonic Acid;
T-Lymphocytes, Helper-Inducer/drug effects*;
Intestinal Mucosa;
Disease Models, Animal
- From:
Journal of Southern Medical University
2025;45(3):595-602
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the therapeutic effects of cimifugin on Crohn's disease (CD)-like colitis in mice and its possible mechanism.
METHODS:Thirty adult male C57BL/6 mice were randomized equally into control group, 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced CD-like colitis model group, and cimifugin treatment (daily gavage at 12.5 mg/kg) group. The therapeutic effect of cimifugin was evaluated by observing changes in body weight, disease activity index (DAI) scores, colon length, histopathological inflammation scores, and inflammatory cytokine levels in the colonic mucosa. Intestinal barrier integrity in the mice was assessed using immunofluorescence assay and Western blotting for claudin-1 and ZO-1; T-helper (Th) cell subset ratios in the mesenteric lymph nodes were analyzed with flow cytometry. Network pharmacology, KEGG enrichment analysis and molecular docking were used to predict the targets of cimifugin and analyze the key pathways and cimifugin-MAPK protein interactions, which were validated by Western blotting in the mouse models.
RESULTS:In mice with TNBS-induced colitis, cimifugin treatment significantly attenuated body weight loss and colon shortening, lowered DAI and histopathological scores, decreased IFN-γ and IL-17 levels, and increased IL-4 and IL-10 levels in the colonic mucosa. Cimifugin treatment also significantly improved TNBS-induced claudin-1 dislocation and reduction of goblet cells, upregulated claudin-1 and ZO-1 expressions, reduced Th1 and Th17 cell percentages, and increased Th2 and Treg cell percentages in the colonic mucosa of the mice. KEGG analysis suggested a possible connection between the effect of cimifugin and MAPK signaling, and molecular docking showed strong binding affinity between cimifugin and MAPK core proteins. Western blotting demonstrated significantly decreased phosphorylation levels of JNK, ERK, and p38 in the colonic mucosa of cimifugin-treated mouse models.
CONCLUSIONS:Cimifugin alleviates TNBS-induced CD-like colitis by repairing intestinal barrier damage and restoring Th1/Th2 and Th17/Treg balance via suppressing MAPK pathway activation.
